Sponsored Links
| Protalix BioTherapeutics Presents Data On The Company's Fabry Program And Oral Enzyme Gaucher Program With Experts In The Field Of Lysosomal Disorders |
 |
 |
 |
| Medical News - Lymphology and Lymphedema | |
|
Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX, TASE: PLX), announced that management presented data on the Company's preclinical Fabry program and oral enzyme Gaucher program with experts in the field of lysosomal disorders at a Company-sponsored medical meeting which was recently held in New York City... Read more: Lymphology/Lymphedema News From Medical News Today
|